CD8A and neoplasm: To determine whether the Liraglutide+αPD‐1 combination therapy induced long‐term antitumor CD8+ T cell responses, we conducted surgical resection of primary tumors on one side of the mice and rechallenged them through administration of respective tumor cell lines on the opposite side.